$PRME

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Prime Medicine (PRME) reported a Q2 2026 net loss of $42.1M, narrower than the prior year. R&D and G&A expenses decreased. The company advanced PM577a and PM647 toward clinical trials, with FDA clearances and data expected in 2027. PM359 received RMAT designation, with a potential BLA filing in 2027. PRME has $108.8M in cash, expected to last into 2027.

TD Cowen reiterated a Buy on Prime Medicine (NASDAQ:PRME) after an arbitration win against Beam Therapeutics. A tribunal ruled PM647 is within Prime’s field under a 2019 collaboration agreement and Prime owes no monetary damages. Prime plans an IND/CTA filing for PM647 in Q3 2026, with initial data in 2027. H.C. Wainwright set an $8 target; Citizens set $6.

Prime Medicine, Inc. (PRME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates -- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initia

Prime Medicine (NASDAQ:PRME) said a tribunal issued a positive, binding resolution in its arbitration with Beam Therapeutics over a 2019 Collaboration and License Agreement. The tribunal found PM647 is within the agreement’s “Field,” so Prime Medicine did not breach and owes no monetary damages. PM647 uses Prime Medicine’s universal liver lipid nanoparticle to edit the SERPINA1 E342K mutation in AATD.

Prime Medicine said it won a dispute with Beam Therapeutics over gene-editing technology rights related to AATD. Prime expects to start an AATD clinical trial this quarter, and its stock rose about 11% while Beam fell about 2%. Beam said it disagrees and may pursue further action, according to company statements.

Prime Medicine shares rose 11.4% after the company said a binding arbitration ruling against Beam Therapeutics resolved rights to develop PM647, a prime editing therapy for AATD. The tribunal said PM647 is within Prime Medicine’s contract “Field,” found no breach, and awarded no monetary damages. Prime Medicine plans to file an IND/CTA in Q3 2026, with initial data in 2027.

Prime Medicine (NASDAQ:PRME) shares rose 11.3% after a binding arbitration ruling against Beam Therapeutics (NASDAQ:BEAM) over development rights to PM647. The tribunal said PM647 is within Prime’s defined “Field” under a 2019 agreement, finding no breach and no monetary damages owed. Prime plans to file an IND/CTA in Q3 2026 and expects initial data in 2027.

Prime Medicine (Nasdaq: PRME) said an arbitration tribunal in its 2019 collaboration with Beam Therapeutics ruled PM647 is within Prime’s “Field,” so Prime did not breach the agreement and owes Beam no monetary damages. Prime plans IND and/or CTA filings for PM647 in Q3 2026, with initial clinical data expected in 2027.

Prime Medicine said New Zealand’s Medsafe cleared its Clinical Trial Application for PM577a, an investigational in vivo prime editing therapy for the H1069Q mutation in Wilson disease. The company plans to start a global Phase 1/2 study in 2H 2026, with safety and biological activity endpoints. It expects initial data in 2027.